Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Zai Lab (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, and Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced topline data for repotrectinib within the China region from the previously disclosed Phase 1/2 TRIDENT-1 study dataset.

Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

Zai Lab's engagement of an audit firm located in the United States is expected to facilitate the Company's continued listing on Nasdaq because KPMG is subject to inspection by the PCAOB Zai Lab's engagement of an audit firm located in the United States is expected to facilitate the Company's continued listing on Nasdaq because KPMG is subject to inspection by the PCAOB

Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company's Independent Registered Public Accounting Firm

-- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET -- Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET

Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022

NEW YORK , April 18, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zai Lab securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB

New York, New York--(Newsfile Corp. - April 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Zai Lab securities you may be entitled to compensation without payment of any out of pocket fees...

ZLAB Investor Notice: ROSEN, A Leading Law Firm, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB

-  First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation

Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting

NEW YORK , April 4, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zai Lab securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ZLAB INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation - ZLAB

LOS ANGELES--(BUSINESS WIRE)---- $ZLAB #ZLAB--The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm

BeiGene

CASI Pharmaceuticals

Hutchison China MediTech Ltd.

According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting stage, the framework from the China Securities Regulatory Commission and other national.

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab Limited (NASDAQ: ZLAB) resulting from allegations that Zai Lab may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zai Lab securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The

EQUITY ALERT: Rosen Law Firm Encourages Zai Lab Limited Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ZLAB

ACM Research

Alibaba

Baidu

Weibo

Yum China Hlds

Weibo Corp (WB), on Wednesday, joined previously identified Chinese stocks that may be delisted from U.S. exchanges. More could follow and Alibaba (BABA) could be in SEC crosshairs too.

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs

Shares of Chinese companies flagged for possible delisting in the U.S. slid in Hong Kong and Shanghai trading Friday, a move that analysts said highlighted geopolitical tensions but would have little immediate impact on the companies' operations.

Dow Jones Newswires: SEC-targeted Chinese companies slump; Yum China warns of 2024 delisting risk

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. The post Which Chinese Stocks Could Get Delisted?

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.

SHANGHAI and SAN FRANCISCO, and CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and the recent pandemic-related restrictions in Shanghai, the format of the extraordinary general meeting of shareholders (EGM) of Zai Lab Limited has been changed and will be held in a virtual meeting format only. The purpose of the EGM is to consider and vote on a proposal relating to a proposed 1-to-10 share subdivision of the ordinary shares of Zai Lab Limited. As previously announced, the EGM will be held on March 28, 2022 at 8:00 a.m. (U.S. Eastern Time) / 8:00 p.m. (Hong Kong Time).

Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today presented data from the Phase 3 PRIME study of ZEJULA (niraparib) as maintenance therapy at the Society of Gynecologic Oncology annual meeting. ZEJULA demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a tolerable safety profile in Chinese patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) following a response to platinum-based chemotherapy, regardless of biomarker status.

Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting

Atlanta, Georgia--(Newsfile Corp. - March 18, 2022) - Holzer & Holzer, LLC is investigating whether Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB) complied with federal securities laws. On March 9, 2022, the SEC published a notification identifying Zai Lab, among others, as being in potential violation of the Holding Foreign Companies Accountable Act. Following this news, the Company's stock price dropped. If you purchased Zai Lab stock and suffered a loss on...

SHAREHOLDER ALERT: Investigation of Zai Lab (ZLAB) Announced by Holzer & Holzer, LLC

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Josh Smiley as its Chief Operating Officer (COO). Mr. Smiley brings over 26 years of experience working within the biopharmaceutical industry, including experience leading finance, corporate strategy, business development, venture capital and the Global Business Services operations at Eli Lilly and Co (Lilly).

Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer

Didi Global

iQIYI

Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next. The post Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?

Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM), have been flagged by the SEC for failing to comply with a law governing US-listed companies. In statements responding.

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today

Bilibili

JD.com

KraneShares CSI China Internet ETF

Pinduoduo Inc - ADR

Shares of many U.S.-listed Chinese stocks tumbled Thursday after the Securities and Exchange Commission put out an update about foreign companies using accounting firms or branches that cannot be adequately inspected.

MarketWatch: U.S.-listed China stocks sink as jitters build about overseas listings

A 2020 law called the Holding Foreign Companies Accountable Act may be behind the sharp decline in a handful of U.S-traded Chinese stocks.

These Chinese stocks are down sharply on Thursday. Here's what could be behind the decline

ZLAB was founded by Samantha Du, the Big Sister of China's emerging pharma industry. The company has an impressive pipeline. Recent US pushback on Chinese drugs makes me wonder whether the current low is an opportunity or a sign of trouble.

Zai Lab: Shares Are Cheap, But Not Without Reason

Zai Lab Limited (ZLAB) CEO Samantha Du on Q4 2021 Results - Earnings Call Transcript

Company to Host Conference Call and Webcast on March 2, 2022, at 8:00 a.m. EST Company to Host Conference Call and Webcast on March 2, 2022, at 8:00 a.m. EST

Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021

--- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and advanced solid tumors --- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and advanced solid tumors

News for Zai Lab Ltd. Stock (ZLAB)